Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Pushes Back Against “Living” Benefit-Risk Assessment Management Plan

May 07 2012

• By Cathy Dombrowski

Related Content

IoM Report On Postmarketing Study Ethics Could Drive Broad Overhaul Of Informed Consent

Jul 12 2010

Post-Market Safety Updates Replaced By “Periodic Benefit-Risk Evaluation Reports”

Apr 10 2012

FDA Transparency Initiative: Disclosure Rules Could Expand, Then Be Harmonized

May 24 2010

PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue

Mar 07 2011

Benefit-Risk Assessment Framework Moves Toward Global Harmonization

Jan 30 2012

CV Risk Assessment For All Obesity Drugs Seems Inevitable Pre-Approval Requirement

Mar 30 2012

PhRMA Wants FDA To Explain When Decisions Depart From Committee Votes

Jun 29 2009

PhRMA Testing Pilot Framework For Structured Benefit-Risk Assessment

Sep 12 2011

BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA

Jul 04 2011

FDA’s Progress On Biomarkers: Two Steps Forward, One Step Back?

Nov 28 2005

Related Companies

GSK plc

Takeda Pharmaceutical Co. Ltd.

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window